Biosceptre is developing targeted therapeutics and immune-oncology products against nfP2X7, a cancer target that has been shown to be present on the majority of cancers. Our goal is to bring novel antibody and CAR T therapeutics to patients suffering from a wide range of malignancies.
View Top Employees from Biosceptre International Limited| Website | http://www.biosceptre.com |
| Revenue | $3 million |
| Funding | $16 million |
| Employees | 19 (18 on RocketReach) |
| Founded | 2000 |
| Phone | +61 2 8115 0900 |
| Fax | +61 2 9490 5038 |
| Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology, Business Services, Science and Engineering, Health Diagnostics, Health Care, Medical |
| Web Rank | 22 Million |
| Competitors | Aduro Biotech Europe, Alethia Biotherapeutics Inc., Arcus Biosciences, Idera Pharmaceuticals, Kiromic Biopharma, Inc. |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies |
Looking for a particular Biosceptre International Limited employee's phone or email?
Biosceptre International Limited Questions
The Biosceptre International Limited annual revenue was $3 million in 2023.
Julian Barden is the Director of Research of Biosceptre International Limited.
18 people are employed at Biosceptre International Limited.
The NAICS codes for Biosceptre International Limited are [541, 5417, 54].
The SIC codes for Biosceptre International Limited are [87, 873].
Top Biosceptre International Limited Employees
-
14
-
View
Braden Roberts
Chief Business Officer at Biosceptre International Limited
New South Wales, Australia1 -
ViewEddie Low
Chief Financial Officer at Biosceptre International Limited
Sydney, New South Wales, Australia1
Related Companies
